References
- Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61
- Park K, Hwang EC, Kim SO. Prevalence and medical management of erectile dysfunction in Asia. Asian J Androl 2011;13:543–9
- Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50–6
- Lam TH, Abdullah AS, Ho LM, et al. Smoking and sexual dysfunction in Chinese males: findings from men's health survey. Int J Impot Res 2006;18:364–9
- Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003;15:63–71
- Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804–14
- Hanson-Divers C, Jackson SE, Lue TF, et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998;159:1541–7
- Souverein PC, Egberts AC, Meuleman EJ, et al. Incidence and determinants of sildenafil (dis)continuation: The Dutch cohort of sildenafil users. Int J Impot Res 2002;14:259–65
- Gonzalgo ML, Brotzman M, Trock BJ, et al. Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003;170:503–6
- Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5:2672–80
- Beckman TJ, Abu-Lebdeh HS, Mynderse LA. Evaluation and medical management of erectile dysfunction. Mayo Clin Proc 2006;81:385–90
- Zhao E, Cui D, Yuan L, et al. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep 2012;39:3471–7
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60
- Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.0.2, updated September 2009. The Cochrane Collaboration 2009
- Paick JS, Choi HK, Kim SC, et al. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl 2008;10:791–8
- Paick JS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil in men taking antihypertensive medications. J Sex Med 2010;7:3143–52
- Park HJ, Choi HK, Ahn TY, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med 2010;7:2842–50
- Chung JH, Kang DH, Oh CY, et al. Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multicenter, double-blind, placebo controlled trial. J Urol 2013;189:1006–13
- Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32:379–95, v
- Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom 2007;21:1139–49
- Berner MM, Kriston L, Harms A. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res 2006;18:229–35
- Ding H, Du W, Wang H, et al. Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. Urology 2012;80:134–9
- Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650–61
- Tsertsvadze A, Yazdi F, Fink HA, et al. Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology 2009;74:831–6 e838
- Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6